This mechanism of action not only preserves ... making them safer for long-term use. Retinitis pigmentosa affects over 100,000 people in the United States alone, with no approved treatments ...

Understanding the mechanisms behind Usher syndrome is ... and the age at which retinitis pigmentosa develops. New research has identified additional genes associated with Usher syndrome, expanding ...

OCU400 showed significant 2-line gain in LLVA in treated eyes, validating its gene-agnostic mechanism for retinitis pigmentosa. The therapy's effectiveness across multiple mutations highlights its ...

Night driving glasses claim to help you see at night when you are behind the wheel. But do they actually work, and are they ...

A new mechanism in blue cone monochromatism ... Rod visual fields in cone-rod degeneration. Comparison to retinitis pigmentosa. Invest Ophthalmol Vis Sci 1990;31:2288–99. Miyake Y, Shiroyama ...

This important Research Advance presents convincing evidence on the neuroprotective effects of reserpine in a well-established model of retinitis pigmentosa (P23H-1 ... to characterize sex- bias ...

The discovery of the underlying genetic causes over the last two decades has led to far greater understanding of disease mechanisms in IRD which ... 63 64 RPGRIP1 is a binding partner of retinitis ...

Scientists have identified two non-retinoid compounds that may be able to treat retinitis pigmentosa (RP), a group of inherited eye diseases that cause blindness. The compounds were discovered by ...

Retinitis pigmentosa is a relatively rare genetic disorder (affecting 1 in 3,500 people), while age-related macular degeneration affects 7–8% of the population, and its incidence increases with age.

Two new compounds may be able to treat retinitis pigmentosa, a group of inherited eye diseases that cause blindness. The compounds, described in a study published January 14 th in the open-access ...

FORT WORTH, Texas, Jan. 21, 2025 (GLOBE NEWSWIRE) -- Nacuity Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company developing treatments for retinitis pigmentosa, cataracts and other ...